Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 455 matching trials from the live ClinicalTrials.gov search.
Conditions
Stable Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CMX-2043, Placebo control
Drug
Lead sponsor
Ischemix, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Worcester, Massachusetts • Durham, North Carolina
Conditions
Alopecia Areata
Interventions
ATI-50002 high dose, ATI-50002 low dose, Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
23
States / cities
Encinitas, California • Laguna Hills, California • Redwood City, California + 18 more
Conditions
Inflammation, Pain, Cataract
Interventions
XG-102, Placebo
Drug
Lead sponsor
Xigen SA
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Andover, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Dry Eye Treatments on the Ocular Surface

NCT01797822
Conditions
Keratoconjunctivitis Sicca, Dry Eye Syndrome
Interventions
Dexamethasone, Artificial tear
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 3 Interventional Results available

Safety Study of Tivanisiran to Treat Dry Eye

NCT05310422
Conditions
Dry Eye Disease
Interventions
Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
Drug
Lead sponsor
Sylentis, S.A.
Industry
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Chandler, Arizona • Phoenix, Arizona • Glendale, California + 21 more
Conditions
Dry Eye Syndrome
Interventions
rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 85 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Glendale, California • Newport Beach, California • Rancho Cordova, California + 7 more
Conditions
Corneal Epithelial Disorders
Interventions
SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic Solution
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Little Rock, Arkansas • Glendale, California • Glendora, California + 14 more
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
Vehicle Ophthalmic Solution, PL9643 Ophthalmic Solution
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Glendale, California • Newport Beach, California • Torrance, California + 15 more
Conditions
Postoperative Chylothorax, Congenital Heart Disease, Open Heart Surgery, Chylothorax
Interventions
Propranolol Hydrochloride, Placebo
Drug
Lead sponsor
June Wu
Other
Eligibility
7 Days to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Preoperative Chlorhexidine Gluconate (CHG) Cloth on Healthy Subjects

NCT02222896
Conditions
Surgery
Interventions
Chlorhexidine Gluconate, Vehicle, DynaHex-2
Drug · Other
Lead sponsor
Medline Industries
Industry
Eligibility
16 Years and older
Enrollment
347 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sterling, Virginia
Conditions
Presbyopia
Interventions
UNR844, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 55 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Laguna Hills, California • Newport Beach, California • Largo, Florida + 8 more
Conditions
Seborrheic Keratosis
Interventions
A-101 Solution, Vehicle Solution
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Malvern, Pennsylvania
Conditions
Knee Injuries
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
15 Years to 65 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
18
States / cities
Encinitas, California • Redwood City, California • Stanford, California + 15 more
Conditions
Cystic Fibrosis
Interventions
Lucinactant first, Placebo first
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
14 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
Interventions
Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
15
States / cities
Laguna Hills, California • Lancaster, California • Cape Coral, Florida + 11 more
Conditions
Dry Eye Syndrome
Interventions
RX-10045, Vehicle for RX-10045
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Seasonal Allergic Conjunctivitis
Interventions
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%, Experimental: Vehicle ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Louisville, Kentucky • Andover, Massachusetts • Goodlettsville, Tennessee + 3 more
Conditions
Dry Eye Disease
Interventions
INV-102, Vehicle
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rush, New York
Conditions
Hyperhidrosis
Interventions
Umeclidinium, Vehicle
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Raleigh, North Carolina • Austin, Texas
Conditions
Stress Urinary Incontinence
Interventions
Placebo, Iltamiocel
Other · Biological
Lead sponsor
Cook MyoSite
Industry
Eligibility
18 Years and older · Female only
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
26
States / cities
Phoenix, Arizona • Agoura Hills, California • Los Angeles, California + 22 more
Conditions
Presbyopia
Interventions
AGN-199201 ophthalmic solution, AGN-190584 ophthalmic solution, AGN-190584 vehicle, AGN-199201 + AGN-190584 Combination, AGN-199201 vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 50 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Artesia, California • Azusa, California • Costa Mesa, California + 17 more
Conditions
Non-Exudative Age Related Macular Degeneration
Interventions
MC-1101, MC-1101 Vehicle
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Murray, Utah
Conditions
Dry Eye Disease
Interventions
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Chemotherapy-Associated Paronychia
Interventions
VBP-926
Drug
Lead sponsor
Veloce BioPharma LLC
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Fountain Valley, California • Chicago, Illinois • St Louis, Missouri + 5 more